Telix Pharmaceuticals submits NDA for Pixclara to advance brain cancer imaging

By on    Healthcare Industry News  

Telix Pharmaceuticals submits NDA for Pixclara to advance brain cancer imaging

Telix Pharmaceuticals Limited (ASX: TLX) has taken a significant step in the realm of neuro-oncology by submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TLX101-CDx, also known as Pixclara (18F-floretyrosine or 18F-FET). This investigational positron emission tomography (PET) imaging agent is designed to enhance the characterization of progressive […]

Telix Pharmaceuticals advances prostate cancer treatment with successful TLX592 study

By on    Pharma Industry News  

Telix Pharmaceuticals advances prostate cancer treatment with successful TLX592 study

Telix Pharmaceuticals Limited (ASX: TLX) has announced the successful completion of the CUPID Phase I dose escalation study of TLX592, marking a significant advancement in targeted alpha therapy (TAT) for prostate cancer. This milestone is especially noteworthy as TLX592 incorporates Telix’s proprietary RADmAb engineered antibody technology, promising a new era in cancer treatment efficacy and […]